Mesenchymal Stromal Cells Clinical Trial
Official title:
Mesenchymal Stromal Cells Treatment in Lyell Syndrome: A Pilot Phase 1-2 Open Trial
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare severe cutaneous adverse reactions (SCARs) to drugs. To date, no curative drug has demonstrated with a good level of evidence its ability to promote SJS and TEN healing and could contribute to earlier reepithelialisation. Mesenchymal stroma cells (MSCs) therapy represents a new therapeutic approach. eg, in patients with cardiovascular diseases, neurological diseases, renal transplantation, lung diseases as acute respiratory distress syndrome. Recently, MSCs have been proposed in both burn wound healing with a significantly decrease of the unhealed burn area and in cutaneous radiation. Moreover, MSCs have immunomodulation properties potentially effective in refractory acute and chronic graft versus host disease (GVHD) by improving thymic function and induction of Tregs. Indeed, MSCs are able to migrate to inflamed tissues after stimulation by pro-inflammatory cytokines and to modulate the local inflammatory reactions. MSCs have also demonstrated their ability to promote tissue remodelling, angiogenesis and immunomodulation through either differentiation or secretion of several growth factors such as VEGF, basic FGF and various cytokines. Therefore, combining their immunomodulation effect and secretion of soluble factors involved in wound repair, MSCs might be valuable as a cell therapy strategy for promoting cutaneous healing in SJS-TEN syndrome and subsequently decrease the morbi-mortality.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
| Completed |
NCT02274428 -
Phase 1 Clinical Trial of PNEUMOSTEM® Treatment in Premature Infants With Intraventricular Hemorrhage
|
Phase 1 | |
| Recruiting |
NCT04626583 -
Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells
|
Phase 1 | |
| Active, not recruiting |
NCT03874572 -
Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth
|
Phase 1 | |
| Recruiting |
NCT04785027 -
Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05602116 -
ASC - Autism Study
|
Phase 1 | |
| Recruiting |
NCT04918706 -
Allogeneic MSC Treatment for Pulmonary Emphysema
|
Phase 2 | |
| Completed |
NCT03392311 -
Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05204329 -
Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
|
Early Phase 1 | |
| Recruiting |
NCT05595681 -
Effect of Mesenchymal Stem Cells on Healing of Foot Ulcers in Diabetes Patients.
|
Phase 1 | |
| Not yet recruiting |
NCT03745417 -
Efficacy and Safety of Expanded UCMSCs On Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT03876197 -
Mesenchymal Stem Cells for Radiation-induced Xerostomia
|
Phase 1/Phase 2 | |
| Terminated |
NCT04371393 -
MSCs in COVID-19 ARDS
|
Phase 3 | |
| Completed |
NCT04275024 -
Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment and PSORI-CM01 Granule in Psoriasis Patients
|
N/A |